Scottsdale, Arizona--(Newsfile Corp. - February 28, 2023) - Inc. magazine revealed that PathogenDx (“PathogenDx” or “Company”), a leader in next-generation microarray technology for better health and safety, is No. 50 on its fourth annual Inc. 5000 Regionals Southwest list1, the most prestigious ranking of the fastest-growing private companies based in Arizona, New Mexico, Oklahoma, and Texas. Born of the annual Inc. 5000 franchise, this regional list represents a unique look at the most successful companies within the Southwest economy’s most dynamic segment - its independent small businesses.

“We are once again honored to be named as one of the fastest growing private companies in the Southwest,” said PathogenDx Co-founder and CEO Milan Patel. “While the pandemic elevated people’s awareness of the dangers of pathogens - viruses and antibiotic-resistant superbugs continue to surge. Just in the last few months alone, we’ve seen: an uptick in polio and monkeypox cases; new strains of parvo killing dogs; the USDA declaring Salmonella an adulterant in chicken products; a multistate Norovirus outbreak from contaminated oysters; antibiotic-resistant gonorrhea strains emerging; and the ‘tripledemic’ of COVID-19, R.S.V. and the flu wreaking havoc on individuals across the world. These issues are not a mere coincidence - they’re a sign that we need to be paying better attention to global health and safety issues. At PathogenDx, we are working hard to develop our next-generation technologies, which have been instrumental in not only saving lives, but also saving significant time and money as we fight these grave public health concerns across multiple sectors.”

“This year’s Inc. 5000 Regional winners represent one of the most exceptional and exciting lists of America’s off-the-charts growth companies,” said Scott Omelianuk, editor-in-chief of Inc. magazine. “They’re disruptors and job creators, and all delivered an outsized impact on the economy. Remember their names and follow their lead. These are the companies you’ll be hearing about for years to come.”

This leader in next-generation microarray technology for better health and safety saw a two-year 276% uptick in revenue, and was the recipient of numerous awards and honors, including: the Deloitte Technology Fast 500, Fast Company World Changing Ideas Award and Inc. 5000. With more than 50 Patents, the Company achieved several industry firsts, such as: securing the first CE mark for COVID-19 Variant testing and AOAC® Performance Tested Methods Certificate for Quantitative Yeast & Mold for a Microarray. PathogenDx also debuted Phytox to curb the spread of new and existing plant-born pathogens currently on the rise; and PathogenDx launched Octa™ AutoPrep Station, an ultra-simple and easy-to-use automated sample preparation system for bacterial and fungal pathogen testing in the cannabis and hemp sectors.

The companies on the Inc. 5000 Regionals Southwest list show a remarkable rate of growth across all industries in the Southwest region. Between 2019 and 2021, these private companies added 16,116 jobs and nearly $5.5 billion to the Southwest region’s economy. Companies based in the Austin, Texas, Scottsdale, Arizona, and Fort Worth, Texas, areas had the highest growth rates overall.

Complete results of the Inc. 5000 Regionals Southwest, including company profiles and an interactive database that can be sorted by industry, metro area, and other criteria, can be found at inc.com/southwest starting February 28, 2023.

About PathogenDx
Headquartered in Scottsdale, Arizona, PathogenDx (“PathogenDx” or “Company”) is a leader in next-generation microarray technology for better health and safety. Its mission is to become the new standard in DNA-based testing through widespread adoption of its advanced microarray testing platform for the human diagnostics, food and agricultural industries. PathogenDx’s technology can rapidly identify and detect up to 50 pathogens all in a single test, in six hours providing triplicate data per analyte for certainty in results with a simple and easy process. The company’s DNA-testing products - Detectx™, Quantx™ and Envirox™ are disrupting the century old practice of petri dish testing to identify, detect and quantify pathogens that threaten human health, our ecosystem and the environment. This technology will help growing businesses deliver safer products leading to healthier lives, while preventing billions of dollars in losses from infection and contamination. For more information on how you can utilize this simple, powerful and inexpensive DNA-based pathogen testing, visit www.pathogendx.com.

About Inc. Media

The world’s most trusted business-media brand, Inc. offers entrepreneurs the knowledge, tools, connections, and community to build great companies. Its award-winning multiplatform content reaches more than 50 million people each month across a variety of channels including websites, newsletters, social media, podcasts, and print. Its prestigious Inc. 5000 list, produced every year since 1982, analyzes company data to recognize the fastest-growing privately held businesses in the United States. The global recognition that comes with inclusion in the 5000 gives the founders of the best businesses an opportunity to engage with an exclusive community of their peers and the credibility that helps them drive sales and recruit talent.

The associated Inc. 5000 Conference is part of a highly acclaimed portfolio of bespoke events produced by Inc. For more information, visit www.inc.com.

Media Contact:
MATTIO Communications
Gaby Seligman
pathogendx@mattio.com

###

1 Methodology: The 2023 Inc. 5000 Regionals are ranked according to percentage revenue growth when comparing 2019 and 2021. To qualify, companies must have been founded and generating revenue by March 31, 2019. They had to be U.S.-based, privately held, for-profit, and independent-not subsidiaries or divisions of other companies-as of December 31, 2021. (Since then, a number of companies on the list have gone public or been acquired.) The minimum revenue required for 2019 is $100,000; the minimum for 2021 is $1 million. As always, Inc. reserves the right to decline applicants for subjective reasons.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/156311